Milrinone Versus Dobutamine in Critically Ill Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

August 30, 2017

Primary Completion Date

June 12, 2020

Study Completion Date

June 12, 2020

Conditions
Low Cardiac Output SyndromeCardiogenic ShockAcute Coronary SyndromePulmonary Edema
Interventions
DRUG

Milrinone

Patients will be initiated on Milrinone at 0.125 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[0.250, 0.375, 0.5 and \>0.5 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.

DRUG

Dobutamine

Patients will be initiated on Dobutamine at 2.5 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[5.0, 7.5, 10 and \>10 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.

Trial Locations (1)

K1Y 4W7

University of Ottawa Heart Institute, Ottawa

All Listed Sponsors
lead

Ottawa Heart Institute Research Corporation

OTHER

NCT03207165 - Milrinone Versus Dobutamine in Critically Ill Patients | Biotech Hunter | Biotech Hunter